Prosthesis-annular length and QRS duration before and immediately after TAVI implantation were compared to the need of permanent pacing.
Materials and methods: retrospective study of 170 patients, hospitalized in the cardiology department between January 1994 and January 2008 having PMC by balloon inoué with a clinical and echocardiographic follow-up of more than 10 years. We defined the patients >=50 years old (group1) and the patients aged less than 50-years (group 2)
Results: -45 patients were >= 50 years old (17,05%). The mean age was 56,41%. 62,1% were in atrial fibrillation (AF) and 37,9% were in sinus rhythm(SR) . The WILKINS score showed that 20,7% had a score <8,72, 4% between 9-11 and 6,9% a score >12. After PMC the mean mitral area was passed from 1,07+-0,2 cm 2 to 2,03+-0,3 cm 2 (p<0,001), the transmitral gradient was passed from 14,88+-5,14 mmhg to 3,99+-2,26 (p<0,001) and the mean pulmonary artery pressure was passed from 35,66 +-9,97 mmhg to 24,34 +-9,48 mmhg (p<0,01) . The estimation of Kaplan-Meier showed that the absence of restenosis was respectively 80,8%;73,1%; 65,4% and 61,5% in 3,5,7 and 10 years. -the Comparison between both groups of the young and the elderly patients showed that in the (group 2) the majority of patients were in SR (91,7%) however in the (group) the majority were in AF (61,7%). In our study, in the (group 2) there were no patients having a high score of WILKINS >11, however in the (group 1) 6,9% had a score of WILKINS >11. Finaly in the (group 2) the percentage of patients having had a restenosis is 14,3%; however in the (group1) restenosis was noted in 38,46%.
Conclusion:
PMC is effective first therapy in patients aged >=50 years with symptomatic mitral stenosis. Objective: To assess the impact of coronary artery disease management on prognosis in patients undergoing transcatheter aortic valve implantation (TAVI).
Methods: 121 patients (53 men, 85±7 years) with severe symptomatic aortic stenosis (Aortic Valve Area [AVA]=0.7±0.2 cm², gradient=43±15 mmHg, LVEF=47±13%, logistic Euroscore 27±13%) underwent TAVI using Medtronic Corevalve ® bioprosthesis. Coronary angiography was performed in all before the procedure. Significant coronary lesions (t50%) were treated by angioplasty one month before the procedure or medically treated (aspirin, statin and betablocker). Revascularization strategy was left free to the clinician appreciation and compared to primary outcome (heart failure, myocardial infarction and mortality).
Results:
Of the 121 patients, 57% exhibited significant coronary artery stenosis (45% monotroncular, 35% bitroncular and 20% tritroncular) with proximal coronary stenosis t70% in 73%. Revascularization was performed in 23 patients (78% with proximal stenosis t70%) and medical treatment in 38 patients (45% with proximal stenosis t70%). TAVI procedure was successfully performed in all patients with AVA and mean LVOT gradient after implantation averaging 2.0±0.4 cm² and 9±4 mmHg, respectively. Mean follow-up duration was 194±23 days. Primary outcome [heart failure (n=10), myocardial infarction (n=1) and mortality (n=27)] was similarly observed in the coronary angioplasty and medical treatment groups (26% vs. 32%; p=0.81). Interestingly, poor outcome was only associated to procedure duration (94±6 min vs. 72±6 min, p=0.015) and greater peak troponin I after procedure (0.98±0.2 vs. 0.24±0.1, p=0.0001). Furthermore, increase in troponin I after TAVI was observed in all patients after the procedure independently to the presence of significant coronary stenosis or to revascularization strategy.
Conclusion:
Coronary artery revascularization before TAVI does not impact clearly on outcome. The association between peak troponin after procedure and prognosis suggests that an alternative strategy to better protect myocardial function should be investigated.
Evaluation of radiation dose during transcatheter aortic valve implantation: Comparison with coronary angiograms and percutaneous coronary interventions
Nicolas Meneveau [Orateur] (1), Vincent Descotes-Genon (1), Paul Luporsi (1), Romain Chopard (1), Sebastien Janin (1), Kais Mrabet (1), Sidney Chocron (2), Francois Schiele (1) (1) CHU Besançon, Cardiologie, Besançon, France (2) CHU Besançon, Chirurgie Cardiaque, Besançon, France Background: Transcatheter aortic valve implantation (TAVI) is a growing cardiac intervention using ionising radiation with deterministic and stochastic effects for the patient as well as for the medical heart team. Dose area product (DAP) evaluates radiation dose and is easily found on the X-ray tube program at the end of the procedure. We aimed to measure the dose of radiation emitted during TAVI, and to compare with coronary angiogram (CA) or percutaneous coronary interventions (PCI).
Methods:
We perform TAVI, CA and PCI in the same cath lab. We compare DAP as noted at the end of each procedure for these 3 types of intervention over the same period (September 2008 to June 2010 . For TAVI, we also analysed the role of technical (femoral vs apical approach) and patient-related features (weight, body surface area).
Results:
During the study period, we consecutively included 37 cases of TAVI, 1230 CA, 89 isolated PCI and 807 CA with ad hoc PCI. DAP was significantly higher in TAVI than in CA alone (83.3 vs 44.9 Gy.cm², p<0.01), but no significant difference was observed between TAVI and PCI and CA/PCI (respectively 70.1 and 90 Gy.cm²). Among TAVI, there was a significant difference between transapical approach and transfemoral approach (80 vs 86.3 Gy.cm² respectively, p=0.05). DAP was also influenced by patient's weight (p <0.01, r²=0.29) and body surface area (p<0.01, r²=0.32).
Conclusion:
The radiation dose related to TAVI is twice that of coronary angiogram, and similar to that of coronary angiogram with ad hoc PCI.
